<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">Neither radiotherapy interruptions nor deaths occurred during the study. Famitinib as a single agent was generally well tolerated. Except one patient with grade 3 adverse event (hematuria), all adverse events were grade 1 or 2 (TableÂ 
 <xref rid="Tab2" ref-type="table">2</xref>). 
</p>
